Related Experiment Video
Updated: Jun 28, 2025

Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
Published on: August 16, 2020
Cross-Domain Feature Disentanglement for Interpretable Modeling of Tumor Microenvironment Impact on Drug Response
Abstract:
High-throughput screening technology has enabled the generation of large-scale drug responses across hundreds of cancer cell lines. There remains a significant gap between in vitro cell lines and actual tumors in vivo in terms of their response to drug treatments yet. This is because tumors consist of a complex cellular composition and histopathology structure, known as the tumor microenvironment (TME), which greatly impacts the drug cytotoxicity against tumor cells. To date, no study has focused on modeling the impact of the TME on clinical drug response. In this study, we postulated that the intricate complexity of an actual tumor can be conceptually simplified into two separable components: cancerous cells and the tumor microenvironment. This assumption allowed us to model the influence of these two constituent parts on drug response through feature disentanglement. We employed a domain adaptation network to decouple and extract features from tumor transcriptional profiles. Specifically, two denoising autoencoders were separately used to extract features from cell lines (source domain) and tumors (target domain) for partial domain alignment and feature decoupling. The private encoder was enforced to extract information only about the TME. Moreover, to ensure generalizability to novel drugs, we employed a graph attention network to learn the latent representation of drugs, enabling us to linearly model the drug perturbation on cellular state in latent space. We validated our model on a benchmark dataset and demonstrated its superior performance in predicting clinical drug response and dissecting the influence of the TME on drug efficacy.
Insights
This study models how the tumor microenvironment (TME) affects cancer drug response. Our method accurately predicts clinical outcomes by separating TME and cancer cell features.
Area of Science:
- Computational biology
- Cancer research
- Pharmacogenomics
Background:
- High-throughput screening generates extensive drug response data in cancer cell lines.
- A significant gap exists between in vitro cell line and in vivo tumor drug response.
- Tumor microenvironment (TME) complexity profoundly impacts drug efficacy, yet its role in drug response modeling is understudied.
Purpose of the Study:
- To develop a computational model that accounts for the tumor microenvironment's influence on clinical drug response.
- To decouple and model the distinct contributions of cancerous cells and the TME to drug response.
- To enhance the prediction of drug efficacy in actual tumors.
Main Methods:
- Utilized a domain adaptation network with denoising autoencoders for feature extraction and decoupling from cell lines and tumors.
- Employed a private encoder to specifically isolate TME-related features.
- Integrated a graph attention network to learn drug representations for modeling drug perturbation in latent space.
Main Results:
- Successfully decoupled features related to cancerous cells and the tumor microenvironment.
- Demonstrated superior performance in predicting clinical drug response compared to existing methods.
- Provided insights into how the TME influences drug efficacy.
Conclusions:
- The proposed model effectively predicts clinical drug response by considering the TME.
- Feature disentanglement is a viable approach to model the complex tumor biology.
- This work bridges the gap between in vitro drug screening and in vivo tumor response.

